Stockreport

C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)

C4 Therapeutics, Inc.  (CCCC) 
NASDAQ:AMEX Investor Relations: ir.chinacache.com
PDF Agreement Focused on Developing DACs With Payloads For Two Oncology Targets, With an Option for a Third Target C4T to Develop Degraders With Payload Properties; Roche t [Read more]